VivoSeq
Infectious Disease

Peritonsillar Abscess

5

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Peritonsillar Abscess is an early-stage landscape with 5 programs across 1 company. The most active players are Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

33/100

Attrition Rate

40/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

5

clinical trials

Unknown status2 · 40%
Withdrawn2 · 40%
Completed1 · 20%

Clinical Trials

Trial Activity

Peritonsillar Abscess: Aspiration Versus Tonsillectomy a Chaud
Unknown status·OOdense University Hospital·N/A·NCT03326661·128 enrolled
The Effect of Adding Pain Relievers to Local Anesthesia Before Preforming Drainage in Peritonsillar Abscess
Unknown status·HHaEmek Medical Center, Israel·N/A·NCT01227200·32 enrolled
Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage
Withdrawn·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT01715610
Penicillin and Metronidazole in Treatment of Peritonsillar Abscess
Completed·HHelsinki University Central Hospital·N/A·NCT01255670·200 enrolled
Medical Versus Surgical Treatment for Peritonsillar Abscesses
Withdrawn·NNova Scotia Health Authority·N/A·NCT04998513

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)